HEADER HYDROLASE 04-OCT-99 1D4L TITLE HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 EC: 3.4.23.16; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 OTHER_DETAILS: SF2 ISOLATE, CHEMICALLY SYNTHESISED PROTEIN SOURCE 4 CORRESPONDS TO THE PROTEASE FROM HIV-1, WITH 4 MUTATIONS PER MONOMER KEYWDS HIV, PROTEASE, INHIBITOR, ANTIVIRAL, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR J.D.TYNDALL,R.C.REID,D.P.TYSSEN,D.K.JARDINE,B.TODD,M.PASSMORE, AUTHOR 2 D.R.MARCH,L.K.PATTENDEN,D.ALEWOOD,S.H.HU,P.F.ALEWOOD,C.J.BIRCH, AUTHOR 3 J.L.MARTIN,D.P.FAIRLIE REVDAT 5 03-NOV-21 1D4L 1 REMARK SEQADV LINK REVDAT 4 04-OCT-17 1D4L 1 REMARK REVDAT 3 24-FEB-09 1D4L 1 VERSN REVDAT 2 01-NOV-00 1D4L 1 HETNAM REVDAT 1 11-OCT-00 1D4L 0 JRNL AUTH J.D.TYNDALL,R.C.REID,D.P.TYSSEN,D.K.JARDINE,B.TODD, JRNL AUTH 2 M.PASSMORE,D.R.MARCH,L.K.PATTENDEN,D.A.BERGMAN,D.ALEWOOD, JRNL AUTH 3 S.H.HU,P.F.ALEWOOD,C.J.BIRCH,J.L.MARTIN,D.P.FAIRLIE JRNL TITL SYNTHESIS, STABILITY, ANTIVIRAL ACTIVITY, AND PROTEASE-BOUND JRNL TITL 2 STRUCTURES OF SUBSTRATE-MIMICKING CONSTRAINED MACROCYCLIC JRNL TITL 3 INHIBITORS OF HIV-1 PROTEASE. JRNL REF J.MED.CHEM. V. 43 3495 2000 JRNL REFN ISSN 0022-2623 JRNL PMID 11000004 JRNL DOI 10.1021/JM000013N REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.L.MARTIN,J.BEGUN,A.SCHINDELER,W.A.WICKRAMASINGHE, REMARK 1 AUTH 2 D.ALEWOOD,P.F.ALEWOOD,D.A.BERGMAN,R.I.BRINKWORTH, REMARK 1 AUTH 3 G.ABBENANTE,D.MARCH,R.C.REID,D.P.FAIRLIE REMARK 1 TITL MOLECULAR RECOGNITION OF MACROCYCLIC PEPTIDOMIMETIC REMARK 1 TITL 2 INHIBITORS BY HIV-1 PROTEASE. REMARK 1 REF BIOCHEMISTRY V. 38 7978 1999 REMARK 1 REFN ISSN 0006-2960 REMARK 1 DOI 10.1021/BI990174X REMARK 1 REFERENCE 2 REMARK 1 AUTH D.MARCH,G.ABBENANTE,D.BERGMAN,R.I.BRINKWORTH, REMARK 1 AUTH 2 W.WICKRAMASINGHE,J.BEGUN,J.L.MARTIN,D.P.FAIRLIE REMARK 1 TITL SUBSTRATE BASED CYCLIC PEPTIDOMIMETICS OF PHE ILE VAL THAT REMARK 1 TITL 2 INHIBIT HIV-1 PROTEASE USING A NOVEL ENZYME BINDING MODE. REMARK 1 REF J.AM.CHEM.SOC. V. 118 3375 1996 REMARK 1 REFN ISSN 0002-7863 REMARK 1 DOI 10.1021/JA953790Z REMARK 1 REFERENCE 3 REMARK 1 AUTH G.ABBENANTE,D.MARCH,D.BERGMAN,P.A.HUNT,B.GARNHAM,R.J.DANCER, REMARK 1 AUTH 2 J.L.MARTIN,D.P.FAIRLIE REMARK 1 TITL REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF REMARK 1 TITL 2 PEPTIDES: DESIGN OF HYDROLYTICALLY STABLE CYCLIC REMARK 1 TITL 3 PEPTIDOMIMETIC INHIBITORS OF HIV-1 PROTEASE. REMARK 1 REF J.AM.CHEM.SOC. V. 117 10220 1995 REMARK 1 REFN ISSN 0002-7863 REMARK 2 REMARK 2 RESOLUTION. 1.75 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.851 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.75 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0010 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.9 REMARK 3 NUMBER OF REFLECTIONS : 18244 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.189 REMARK 3 FREE R VALUE : 0.231 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 9.800 REMARK 3 FREE R VALUE TEST SET COUNT : 1791 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.005 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.75 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.86 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 86.10 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2459 REMARK 3 BIN R VALUE (WORKING SET) : 0.2810 REMARK 3 BIN FREE R VALUE : 0.3200 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 9.30 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 251 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.020 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1489 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 58 REMARK 3 SOLVENT ATOMS : 121 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 10.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 19.50 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.00000 REMARK 3 B22 (A**2) : 0.00000 REMARK 3 B33 (A**2) : 0.00000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.18 REMARK 3 ESD FROM SIGMAA (A) : 0.23 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.23 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.27 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.500 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 27.30 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.420 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.430 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.240 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.510 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 4.170 ; 2.500 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO REMARK 3 PARAMETER FILE 2 : NAL.PAR REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : TOPHCSDX.PRO REMARK 3 TOPOLOGY FILE 2 : INHIBITER1.TOP REMARK 3 TOPOLOGY FILE 3 : TOPH19.SOL REMARK 3 TOPOLOGY FILE 4 : SO4.INP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1D4L COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-OCT-99. REMARK 100 THE DEPOSITION ID IS D_1000009785. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 08-MAY-98 REMARK 200 TEMPERATURE (KELVIN) : 298.0 REMARK 200 PH : 5.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU200 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IIC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 59019 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.750 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.5 REMARK 200 DATA REDUNDANCY : 3.380 REMARK 200 R MERGE (I) : 0.08300 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 9.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.75 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.83 REMARK 200 COMPLETENESS FOR SHELL (%) : 84.6 REMARK 200 DATA REDUNDANCY IN SHELL : 3.35 REMARK 200 R MERGE FOR SHELL (I) : 0.30200 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 43.18 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.16 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: AMMONIUM SULFATE. ACETATE BUFFER, , PH REMARK 280 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293.0K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.72000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 30.85500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.38500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 30.85500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.72000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.38500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5450 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9000 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -58.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 41 CG CD CE NZ REMARK 470 LYS A 43 CG CD CE NZ REMARK 470 LYS A 45 CG CD CE NZ REMARK 470 GLU B 21 CG CD OE1 OE2 REMARK 470 ASN B 37 CG OD1 ND2 REMARK 470 LYS B 41 CG CD CE NZ REMARK 470 LYS B 43 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 79 69.07 -68.86 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 503 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PI9 A 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1B6J RELATED DB: PDB REMARK 900 1B6J CONTAINS A SIMILAR N-TERMINAL MACROCYLIC HIV-1 PROTEASE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1B6L RELATED DB: PDB REMARK 900 1B6L CONTAINS A SIMILAR N-TERMINAL MACROCYLIC HIV-1 PROTEASE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1B6N RELATED DB: PDB REMARK 900 1B6N CONTAINS A SIMILAR N-TERMINAL MACROCYLIC HIV-1 PROTEASE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1B6O RELATED DB: PDB REMARK 900 1B6O CONTAINS A SIMILAR N-TERMINAL MACROCYLIC HIV-1 PROTEASE REMARK 900 INHIBITOR DBREF 1D4L A 1 99 UNP P03369 POL_HV1A2 57 155 DBREF 1D4L B 1 99 UNP P03369 POL_HV1A2 57 155 SEQADV 1D4L LYS A 7 UNP P03369 GLN 63 ENGINEERED MUTATION SEQADV 1D4L ILE A 33 UNP P03369 LEU 89 ENGINEERED MUTATION SEQADV 1D4L ABA A 67 UNP P03369 CYS 123 ENGINEERED MUTATION SEQADV 1D4L ABA A 95 UNP P03369 CYS 151 ENGINEERED MUTATION SEQADV 1D4L LYS B 7 UNP P03369 GLN 63 ENGINEERED MUTATION SEQADV 1D4L ILE B 33 UNP P03369 LEU 89 ENGINEERED MUTATION SEQADV 1D4L ABA B 67 UNP P03369 CYS 123 ENGINEERED MUTATION SEQADV 1D4L ABA B 95 UNP P03369 CYS 151 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET ASN LEU PRO SEQRES 4 A 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 A 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ABA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET ASN LEU PRO SEQRES 4 B 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 B 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ABA THR LEU ASN PHE MODRES 1D4L ABA A 67 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1D4L ABA A 95 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1D4L ABA B 67 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1D4L ABA B 95 ALA ALPHA-AMINOBUTYRIC ACID HET ABA A 67 6 HET ABA A 95 6 HET ABA B 67 6 HET ABA B 95 6 HET SO4 A 502 5 HET SO4 A 503 5 HET PI9 A 201 45 HET SO4 B 501 5 HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM SO4 SULFATE ION HETNAM PI9 (10S,13S,1'R)-13-[1'-HYDROXY-2'-(N-P- HETNAM 2 PI9 AMINOBENZENESULFONYL-1''-AMINO-3''-METHYLBUTYL)ETHYL]- HETNAM 3 PI9 8,11-DIOXO-10-ISOPROPYL-2-OXA-9,12-DIAZABICYCLO HETNAM 4 PI9 [13.2.2]NONADECA-15,17,18-TRIENE FORMUL 1 ABA 4(C4 H9 N O2) FORMUL 3 SO4 3(O4 S 2-) FORMUL 5 PI9 C32 H48 N4 O6 S FORMUL 7 HOH *121(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 86 THR B 91 1 6 SHEET 1 A 4 GLN A 2 THR A 4 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 O THR A 96 N ASN B 98 SHEET 4 A 4 GLN B 2 THR B 4 -1 N ILE B 3 O LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 48 0 SHEET 2 B 8 PHE A 53 ILE A 66 -1 N ILE A 54 O ILE A 47 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O HIS A 69 N ILE A 66 SHEET 4 B 8 VAL A 32 ILE A 33 1 N ILE A 33 O LEU A 76 SHEET 5 B 8 ILE A 84 ILE A 85 -1 N ILE A 84 O VAL A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 O LEU A 23 N ILE A 85 SHEET 7 B 8 LEU A 10 ILE A 15 -1 N VAL A 11 O ALA A 22 SHEET 8 B 8 PHE A 53 ILE A 66 -1 N GLU A 65 O ARG A 14 SHEET 1 C 8 LYS B 43 GLY B 49 0 SHEET 2 C 8 GLY B 52 ILE B 66 -1 O GLY B 52 N GLY B 49 SHEET 3 C 8 HIS B 69 GLY B 78 -1 O HIS B 69 N ILE B 66 SHEET 4 C 8 THR B 31 GLU B 34 1 O THR B 31 N LEU B 76 SHEET 5 C 8 ILE B 84 ILE B 85 -1 N ILE B 84 O VAL B 32 SHEET 6 C 8 GLN B 18 LEU B 24 1 O LEU B 23 N ILE B 85 SHEET 7 C 8 LEU B 10 ILE B 15 -1 N VAL B 11 O ALA B 22 SHEET 8 C 8 GLY B 52 ILE B 66 -1 N GLU B 65 O ARG B 14 LINK C ILE A 66 N ABA A 67 1555 1555 1.33 LINK C ABA A 67 N GLY A 68 1555 1555 1.33 LINK C GLY A 94 N ABA A 95 1555 1555 1.33 LINK C ABA A 95 N THR A 96 1555 1555 1.33 LINK C ILE B 66 N ABA B 67 1555 1555 1.33 LINK C ABA B 67 N GLY B 68 1555 1555 1.33 LINK C GLY B 94 N ABA B 95 1555 1555 1.33 LINK C ABA B 95 N THR B 96 1555 1555 1.34 SITE 1 AC1 6 GLY A 68 HIS A 69 LYS A 70 HOH A 353 SITE 2 AC1 6 PRO B 1 LYS B 55 SITE 1 AC2 5 PRO A 1 ABA A 67 HIS A 69 HOH A 363 SITE 2 AC2 5 HOH A 417 SITE 1 AC3 4 ARG A 14 ARG B 14 GLY B 16 GLY B 17 SITE 1 AC4 22 ASP A 25 GLY A 27 ALA A 28 ASP A 29 SITE 2 AC4 22 GLY A 48 GLY A 49 ILE A 50 PRO A 81 SITE 3 AC4 22 VAL A 82 ILE A 84 HOH A 301 ARG B 8 SITE 4 AC4 22 ASP B 25 GLY B 27 ALA B 28 ASP B 30 SITE 5 AC4 22 VAL B 32 GLY B 48 GLY B 49 ILE B 50 SITE 6 AC4 22 VAL B 82 ILE B 84 CRYST1 51.440 58.770 61.710 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019440 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017015 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016205 0.00000